Table 1.
Demographics | |
---|---|
N | 20 |
Age (mean (SD)) | 45.5 (12.4) |
Male (%) | 8 (40) |
Phenotype (%) | |
Primary progressive MS | 3 (15) |
Relapsing-remitting MS | 12 (60) |
Secondary progressive MS | 5 (25) |
Disease Duration (mean (SD)) | 15.1 (9.0) |
EDSS (median (range)) | 2.5 (1.0–7.0) |
Treatments (%) | |
Untreated | 6 (30) |
Glatiramer acetate | 1 (5) |
Interferon beta-1a | 4 (20) |
Dimethyl fumarate | 6 (30) |
Fingolimod | 1 (5) |
Natalizumab | 1 (5) |
Rituximab | 1 (5) |